Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload.
Ann Hematol
; 73(6): 279-81, 1996 Dec.
Article
em En
| MEDLINE
| ID: mdl-9003157
ABSTRACT
In some patients compliance to subcutaneous desferrioxamine therapy is reduced because of allergic symptoms. Effective drug desensitization consists of bringing patients to tolerate the same mode of administration. We evaluated three thalassemic patients with severe allergies to desferrioxamine. Each patient received weekly three prefilled infusors with desferrioxamine 4 g/48 m1/48 h for s.c. therapy. Follow-up was performed for 12 consecutive weeks. During follow-up no allergic events were noted. The s-ferritin levels decreased from 2583 micrograms/l +/- 485 to 1916 micrograms/l +/- 275 (mean decrease 25.8%, p = 0.038). Compliance to the infusional system was excellent. Our results show that continuous infusion of desferrioxamine using a new infusional delivery system is effective in preventing allergic reactions and in reducing iron overload.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
/
Agentes_cancerigenos
Base de dados:
MEDLINE
Assunto principal:
Desferroxamina
/
Hipersensibilidade a Drogas
/
Hemocromatose
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Ann Hematol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
1996
Tipo de documento:
Article
País de afiliação:
Itália